Investors in Capricor Therapeutics Are Invited to Join Securities Fraud Lawsuit

Investors Have the Opportunity to Take Action

Investors who have suffered losses of more than $100,000 in Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities from October 9, 2024, to July 10, 2025, have an important opportunity on the horizon. The Rosen Law Firm, known for its extensive work in investor rights, is reaching out to those who have been affected by the alleged securities fraud perpetrated by Capricor. The firm is encouraging potential claimants to step forward as the court deadline for becoming a lead plaintiff approaches on September 15, 2025.

Why You Should Act Now

If you purchased shares of Capricor during the specified Class Period, you might qualify for financial compensation under a contingency arrangement that doesn’t require any upfront payment. This is an appealing option for those who may feel uncertain about the legal financial burden. To join the class action, concerned investors can visit the Rosen Law Firm’s website or directly contact attorney Phillip Kim, whose experience in securities litigation can provide much-needed guidance through the claims process.

The Heart of the Allegations

According to the filed lawsuit, the claims hinge on Capricor’s misleading statements regarding its lead therapy candidate, deramiocel, aimed at treating cardiomyopathy related to Duchenne muscular dystrophy (DMD). Allegations imply that during the Class Period, Capricor represented its drug's approval prospects by overstating the FDA's potential approval for a Biologics License Application (BLA) while downplaying safety issues derived from the Phase 2 HOPE-2 trial data.

Investors are now asserting that such statements caused Capricor's stock prices to inflate artificially, leading many to invest at an artificially high valuation. Once the accurate, adverse information leaked into the public domain, the stock plummeted, resulting in substantial financial losses for shareholders.

Understanding Your Options

For investors who want to join this legal action, early engagement is critical. While no class has yet been certified, acting soon may provide better leverage in this legal setting. Interested parties can submit necessary documentation to affirm their transaction data and express their desire to join the suit by the approaching deadline.

Additionally, Rosen Law Firm advises all participating investors to remain vigilant in selecting capable legal counsel, emphasizing that the firm itself comes highly recommended due to its proven track record in leading similar cases. Investors should remain cautious of firms merely acting as middlemen in these situations.

The Rosen Law Firm’s Credentials

With a strong focus on securities class action lawsuits, the Rosen Law Firm has a stellar history, achieving record settlements such as the largest securities class action against a company from China at one point. Their achievements consistently rank them among the top firms in the field, recovering significant amounts for clients over the years, including a remarkable $438 million in 2019 alone.

It is crucial for any investor contemplating legal action to understand that you can remain an absent class member without any financial or legal obligation at this moment. However, those wishing to influence the litigation should act decisively and within the legal timeframes provided.

In Summary

Investors of Capricor Therapeutics, Inc. have a specific window to assert their claims regarding alleged securities fraud. The upcoming September 15, 2025, date stands as a pivotal moment for those interested in leading roles within this potential class action. Investors should contact the Rosen Law Firm to discuss their options or follow them on social media for continued updates. Remember, this legal action may be a critical path toward recovering losses.

For more information, interested parties can visit the Rosen Law Firm’s official site or reach out using the provided contact details. Time is of the essence, and investors are urged to act promptly to ensure their voices are heard in this pressing matter.